{
    "clinical_study": {
        "@rank": "68785", 
        "arm_group": {
            "arm_group_label": "Lenalidomide, Dexamethasone, and MEDI-551", 
            "arm_group_type": "Experimental", 
            "description": "Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles.  MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4."
        }, 
        "brief_summary": {
            "textblock": "This research study is being done to see if combining the investigational chemotherapy drug,\n      MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your\n      myeloma cancer stem cells."
        }, 
        "brief_title": "Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "To explore the effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer\n      stem cells (CSCs). Myeloma CSCs will be assessed by a clonogenic assay from the bone marrow\n      and flow cytometry from peripheral blood."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 or older at the time screening\n\n          -  Symptomatic, previously untreated (with exception of corticosteroids) secretory\n             myeloma\n\n          -  Written informed consent obtained from the patient/legal representative prior to\n             performing any protocol-related procedures, including screening evaluations\n\n          -  Patient must agree to take Lenalidomide with low dose dexamethasone as their initial\n             therapy.\n\n          -  ECOG performance status of 0, 1, or 2.\n\n          -  Life expectancy of >6 months\n\n          -  Serum creatinine \u2264 2\n\n          -  ANC\u22651000\n\n          -  Platelets \u2265 50,000\n\n          -  Total bilirubin \u2264 2 x ULN\n\n          -  AST (SGOT) and ALT (SGPT) \u2264 3 x ULN\n\n          -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients\n             intolerant to ASA may use warfarin or low molecular weight heparin)\n\n        Exclusion Criteria:\n\n          -  Any condition that, in the opinion of the investigator, would interfere with\n             evaluation of the investigational product or interpretation of patient safety or\n             study results.\n\n          -  Concurrent enrollment in another clinical study, except for non-interventional,\n             observational studies.\n\n          -  Any chemotherapy, immunotherapy, biologic, investigational, for treatment of multiple\n             myeloma other than Lenalidomide and dexamethasone.\n\n          -  Previous monoclonal antibody (mAb) or other treatment specifically directed against\n             CD19.\n\n          -  History of serious allergy or reaction to any component of the MEDI-551 formulation\n             that would prevent administration.\n\n          -  Previous systemic cancer therapy for myeloma.\n\n          -  Any active secondary malignancy.\n\n          -  Human immunodeficiency virus (HIV) positive serology or acquired immune deficiency\n             syndrome.\n\n          -  Active hepatitis B as defined by seropositivity for hepatitis B surface antigen.  Or\n             patients with positive hepatitis B core antibody titers.\n\n          -  Patients with hepatitis C antibody will be eligible provided that they do not have\n             elevated liver transaminases or other evidence of active hepatitis.\n\n          -  Documented current central nervous system involvement by multiple myeloma.\n\n          -  Previous medical history or evidence of an intercurrent illness that may, in the\n             opinion of the investigator, compromise the safety of the patient in the study.\n\n          -  Diagnosis of plasma cell leukemia\n\n          -  Diagnosis of POEMS syndrome\n\n          -  Diagnosis of Amyloidosis\n\n          -  Diagnosis of non-secretory myeloma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861340", 
            "org_study_id": "J1340", 
            "secondary_id": "NA_00081182"
        }, 
        "intervention": {
            "arm_group_label": "Lenalidomide, Dexamethasone, and MEDI-551", 
            "description": "Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.", 
            "intervention_name": "Lenalidomide, Dexamethasone, and MEDI-551", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Lenalidomide", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "huffca@jhmi.edu", 
                "last_name": "Carol Ann Huff, MD", 
                "phone": "443-287-7104"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "The Sidney Kimmel Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Carol Ann Huff, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of Lenalidomide and Dexamethasone in Combination With MEDI-551 in Previously Untreated Multiple Myeloma.", 
        "other_outcome": {
            "measure": "The pharmacodynamics (reduction in B cells) of this combination", 
            "safety_issue": "No", 
            "time_frame": "28 weeks"
        }, 
        "overall_contact": {
            "email": "huffca@jhmi.edu", 
            "last_name": "Carol Ann Huff, MD", 
            "phone": "443-287-7104"
        }, 
        "overall_official": {
            "affiliation": "The Johns Hopkins University", 
            "last_name": "Carol Ann Huff, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs).", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861340"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The safety of Medi-551 when combined with Lenalidomide and dexamethasone.", 
            "safety_issue": "Yes", 
            "time_frame": "28 weeks"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}